Viemed Healthcare, Inc.
Viemed Healthcare, Inc. (VMD) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Viemed Healthcare, Inc. (VMD), covering cash flow, earnings, and balance sheets.
Viemed Healthcare, Inc. (VMD) Income Statement & Financial Overview
View the income breakdown for Viemed Healthcare, Inc. VMD across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $59.13M | $60.70M | $58.004M | $54.97M |
| Cost of Revenue | $25.85M | $24.56M | $23.63M | $22.45M |
| Gross Profit | $33.28M | $36.14M | $34.37M | $32.52M |
| Gross Profit Ratio | $0.56 | $0.60 | $0.59 | $0.59 |
| R&D Expenses | $797000.00 | $803000.00 | $757000.00 | $758000.00 |
| SG&A Expenses | $28.43M | $29.73M | $28.38M | $27.90M |
| Operating Expenses | $29.22M | $29.69M | $28.74M | $29.22M |
| Total Costs & Expenses | $55.07M | $48.65M | $52.38M | $51.67M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $179000.00 | $147000.00 | $225000.00 | $254000.00 |
| Depreciation & Amortization | $348000.00 | $6.37M | $6.41M | $6.31M |
| EBITDA | $4.10M | $12.82M | $12.13M | $10.50M |
| EBITDA Ratio | $0.07 | $0.21 | $0.21 | $0.19 |
| Operating Income | $3.84M | $6.45M | $5.63M | $3.29M |
| Operating Income Ratio | $0.06 | $0.11 | $0.10 | $0.06 |
| Other Income/Expenses (Net) | -$179000.00 | -$147000.00 | -$129000.00 | -$1.37M |
| Income Before Tax | $3.66M | $6.30M | $5.50M | $2.25M |
| Income Before Tax Ratio | $0.06 | $0.10 | $0.09 | $0.04 |
| Income Tax Expense | $952000.00 | $1.88M | $1.59M | $768000.00 |
| Net Income | $2.63M | $4.32M | $3.88M | $1.47M |
| Net Income Ratio | $0.04 | $0.07 | $0.07 | $0.03 |
| EPS | $0.07 | $0.11 | $0.10 | $0.04 |
| Diluted EPS | $0.06 | $0.10 | $0.10 | $0.04 |
| Weighted Avg Shares Outstanding | $39.43M | $39.03M | $38.87M | $38.82M |
| Weighted Avg Shares Outstanding (Diluted) | $41.63M | $41.52M | $40.78M | $40.55M |
Over the past four quarters, Viemed Healthcare, Inc. demonstrated steady revenue growth, increasing from $54.97M in Q2 2024 to $59.13M in Q1 2025. Operating income reached $3.84M in Q1 2025, maintaining a consistent 6% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $4.10M, reflecting operational efficiency. Net income dropped to $2.63M, with EPS at $0.07. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan